Following on from information provided to NICE by the company in September 2018, the appraisal of Multiple myeloma - elotuzumab (with pomalidomide and dexamethasone, after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1467 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2018, the appraisal of Multiple myeloma - elotuzumab (with pomalidomide and dexamethasone, after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 September 2018 | Suspended. Suspended |
| 28 August 2018 - 25 September 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 18 September 2018 | The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of elotuzumab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma ID1467. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that is developing elotuzumab have shared confidential information with NICE. In light of this information the Institute will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will be closed early. The topic will still progress to Technology Appraisal stage If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar at michelle.adhemar@nice.org.uk |
| 13 February 2018 | Referral |
| 13 February 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual